Time filter

Source Type

Gu W.,Kings College London Bhf Center | Hong X.,Kings College London Bhf Center | Potter C.,Kings College London Bhf Center | Qu A.,Capital Medical University | Xu Q.,Kings College London Bhf Center
Microcirculation | Year: 2017

In recent years, MSCs have emerged as a promising therapeutic cell type in regenerative medicine. They hold great promise for treating cardiovascular diseases, such as myocardial infarction and limb ischemia. MSCs may be utilized in both cell-based therapy and vascular graft engineering to restore vascular function, thereby providing therapeutic benefits to patients. The efficacy of MSCs lies in their multipotent differentiation ability toward vascular smooth muscle cells, endothelial cells and other cell types, as well as their capacity to secrete various trophic factors, which are potent in promoting angiogenesis, inhibiting apoptosis and modulating immunoreaction. Increasing our understanding of the mechanisms of MSC involvement in vascular regeneration will be beneficial in boosting present therapeutic approaches and developing novel ones to treat cardiovascular diseases. In this review, we aim to summarize current progress in characterizing the in vivo identity of MSCs, to discuss mechanisms involved in cell-based therapy utilizing MSCs, and to explore current and future strategies for vascular regeneration. © 2016 John Wiley & Sons Ltd


Wong M.M.,Kings College London Bhf Center | Hong X.,Kings College London Bhf Center | Karamariti E.,Kings College London Bhf Center | Hu Y.,Kings College London Bhf Center | Xu Q.,Kings College London Bhf Center
Journal of Visualized Experiments | Year: 2015

The construction of vascular conduits is a fundamental strategy for surgical repair of damaged and injured vessels resulting from cardiovascular diseases. The current protocol presents an efficient and reproducible strategy in which functional tissue engineered vessel grafts can be generated using partially induced pluripotent stem cell (PiPSC) from human fibroblasts. We designed a decellularized vessel scaffold bioreactor, which closely mimics the matrix protein structure and blood flow that exists within a native vessel, for seeding of PiPSC-endothelial cells or smooth muscle cells prior to grafting into mice. This approach was demonstrated to be advantageous because immune-deficient mice engrafted with the PiPSC-derived grafts presented with markedly increased survival rate 3 weeks after surgery. This protocol represents a valuable tool for regenerative medicine, tissue engineering and potentially patient-specific cell-therapy in the near future. © 2015 Journal of Visualized Experiments.

Loading Kings College London Bhf Center collaborators
Loading Kings College London Bhf Center collaborators